2081eTiP KEYMAKER-U01 phase II substudies 01H/01I: Ifinatamab deruxtecan (I-DXd), raludotatug deruxtecan (R-DXd), or docetaxel in stage IV non-small cell lung cancer (NSCLC) | Publicación